Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Update on Lupus Erythematosus and Dermatomyositis
Description
The discussion focuses on lupus erythematosus and dermatomyositis, highlighting the classification, treatment, and emerging therapies for these connective tissue diseases. Different forms of cutaneous lupus erythematosus (CLE) are introduced, and the importance of accurate diagnosis for systemic lupus erythematosus (SLE) is emphasized, particularly that an Antinuclear Antibody (ANA) test is crucial in diagnosing SLE. Screening for renal involvement in patients with localized discoid lupus is recommended. Treatment strategies include sun protection, topical therapies, and systemic medications like hydroxychloroquine and immunosuppressants for more severe cases. The impact of certain medications, such as proton pump inhibitors on subacute cutaneous lupus erythematosus (SCLE), is emphasized, with research showing significant drug reactivity. Advances in treatment include novel biologics targeting type I interferons, and promising results with treatments like anifrolumab and litifilimab. For dermatomyositis, diagnosis remains challenging due to overlapping symptoms with lupus, but new criteria now allow for diagnosis based on skin manifestations alone, improving early detection. Treatment approaches mirror those of lupus, with an emphasis on managing cancer risk among such patients. Various ongoing studies aim to refine treatment efficacy and explore new therapies for both conditions, showcasing the evolution of understanding and managing these autoimmune diseases.
View moreConclusions
- Lupus is a spectrum disease, with cutaneous lupus often indicating potential systemic involvement.
- Classification criteria for systemic lupus erythematosus (SLE) have been refined, requiring a positive ANA test.
- Patients with discoid lupus erythematosus may still develop systemic disease, thus regular monitoring is necessary.
- Drugs can induce subacute cutaneous lupus erythematosus (SCLE), with proton pump inhibitors being a common culprit.
- Smoking exacerbates cutaneous lupus and is associated with more severe disease.
- Hydroxychloroquine remains a first-line treatment with about 55% efficacy in responding patients.
- Quinacrine may be added to hydroxychloroquine for better management in some cases.
- Immunosuppressive therapies can provide improvement in roughly 50% of patients who do not respond to antimalarials.
- New therapeutic agents such as anifrolumab and litifilimab show promise for treating cutaneous lupus lesions.
- The interferon signature in patients correlates with the severity of skin involvement in lupus.
- Ongoing studies suggest a potential role for newer drugs targeting specific pathways involved in lupus pathogenesis.
- Martin Aringer et al. Ann Rheum Dis 2019;78:1151-1159
- Dzionek A, et al. J Exp Med. 2001;194(12):1823-1834
- Fanning SL, et al. J Immunol. 2006;177(9):5829-5839
- Cao W, et al. PLoS Biol. 2007;5(10):e248
- Röck J, et al. Eur J Immunol. 2007;37(12):3564-3575
- Pellerin A, et al. EMBO Mol Med. 2015;7(4):464-476
- Zeidl M, Chansky PB, Werth VP. Acute onset/flares of dermatomyositis following ingestion of IsaLean herbal supplement: clinical and immunostimulatory findings. Journal of the American Academy of Dermatology, 2018
- Barak V, Halperin T, Kalickman I. The effect of Sambucol, a black elderberry-based, natural product, on the immune response in healthy adults. 2011
- Lundberg IE, et al. Ann Rheum Dis 76:1955-1964, 2017
- Patel B et al, JAAD 79:77-83, 2018
- A. Ravishankar and Werth VP, et al. JAAD, in press
- Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.
- Aggarwal R et al, N Engl J Med 2022; 387:1264-1278.